AMMF Hosts International Cholangiocarcinoma Conference

AMMF Hosts International Cholangiocarcinoma Conference 2018 in UK on Latest Advances for World’s Second Most Common Primary Liver Cancer Which Continues to See Worrying Rise in New Cases Amongst Younger People

AMMF, the only charity in the UK dedicated to cholangiocarcinoma (bile duct cancer) will again bring together scientists, researchers, medics and patients from across the globe at its BASL endorsed conference on 10 May 2018 from 08:30 – 20:00 at the Radisson Blu Hotel, Stansted Airport, Essex.

The conference programme will include updates from leading UK and international experts on issues ranging from surgery for cholangiocarcinoma to the latest clinical trials and targeted therapies for cancer, including the use of radiation therapy (RT). This year will also see the official presentation of the new AMMF Cholangiocarcinoma Scholarship, a 3-year PhD award funded by the charity to specifically to investigate the role of mutations in cholangiocarcinoma. Mollie King, the first recipient of the Scholarship, will be based at The Boulter Lab, located in the MRC Human Genetics Unit at the University of Edinburgh and one of the UK’s foremost laboratories researching cholangiocarcinoma.

As well as Two Patient Speakers, the 13 Specialist Presenters at this year’s Conference include: –

Dr Shahid Khan, Imperial College London
Dr Hayley Whitaker, University College London
Dr Simon Rushbrook Norfolk & Norwich University Hospital
Professor David Bates, University of Nottingham
Mr Marc Quinn, University of Liverpool
Dr Luke Boulter, University of Edinburgh
Dr Ben Dwyer, University of Edinburgh
Professor Richard Syms, Imperial College London
Professor Robert Goldin, Imperial College London
Mr Hassan Malik, Aintree University Hospital
Dr Chris Wadsworth, Imperial College London
Professor Maria Hawkins, University of Oxford
Professor Juan Valle, The Christie, Manchester

As Helen Morement, founder and CEO of the AMMF explains, “Although cholangiocarcinoma (bile duct cancer) is the second most common primary liver cancer in the world, with an increasing incidence globally, and despite its appalling survival rates due to late diagnosis and few treatment options, it remains poorly understood and under-researched. AMMF’s annual cholangiocarcinoma conference is a key platform, unique in the UK, for international experts to share news and information about clinical studies and latest research. The findings bring the prospect of early diagnosis and more effective treatments one step closer.”

“The fact that the conference is now BASL endorsed will help to signpost AMMF as a UK organisation committed to advancing knowledge and understanding of the biology and pathology of the liver in our specialised field, as we work towards better diagnostic techniques, treatments, and ultimately a cure, for this devastating cancer.”

Comments
Loading...